Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

7.96EUR
20 Jul 2018
Change (% chg)

€-0.04 (-0.50%)
Prev Close
€8.00
Open
€8.00
Day's High
€8.06
Day's Low
€7.95
Volume
21,239
Avg. Vol
69,290
52-wk High
€13.47
52-wk Low
€7.65

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.46
Market Cap(Mil.): €236.71
Shares Outstanding(Mil.): 29.59
Dividend: --
Yield (%): --

Financials

  NCOX.PA Industry Sector
P/E (TTM): -- 29.12 33.34
EPS (TTM): -0.37 -- --
ROI: -5.93 13.60 13.18
ROE: -7.13 15.30 15.09

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017

May 04 2018

BRIEF-Nicox Opening Of U.S. Development Office In Research Triangle Park, North Carolina

* REG-NICOX: OPENING OF U.S. DEVELOPMENT OFFICE IN RESEARCH TRIANGLE PARK, NORTH CAROLINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 25 2018

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

Mar 14 2018

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

Mar 06 2018

Earnings vs. Estimates